Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

635 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Entecavir treatment for chronic hepatitis B: adaptation is not needed for the majority of naïve patients with a partial virological response.
Zoutendijk R, Reijnders JG, Brown A, Zoulim F, Mutimer D, Deterding K, Petersen J, Hofmann WP, Buti M, Santantonio T, van Bömmel F, Pradat P, Oo Y, Luetgehetmann M, Berg T, Hansen BE, Wedemeyer H, Janssen HL; VIRGIL Surveillance Study Group. Zoutendijk R, et al. Among authors: buti m. Hepatology. 2011 Aug;54(2):443-51. doi: 10.1002/hep.24406. Hepatology. 2011. PMID: 21563196 Clinical Trial.
Adefovir serum levels do not differ between responders and nonresponders.
Deterding K, Naesens L, Buti M, Janssen H, Kirschner J, Guerrero A, Reijnders J, Neyts J, Zoulim F, Wedemeyer H. Deterding K, et al. Among authors: buti m. J Viral Hepat. 2011 Jul;18(7):e175-8. doi: 10.1111/j.1365-2893.2010.01404.x. Epub 2011 Jan 7. J Viral Hepat. 2011. PMID: 21692930
Virological response to entecavir is associated with a better clinical outcome in chronic hepatitis B patients with cirrhosis.
Zoutendijk R, Reijnders JG, Zoulim F, Brown A, Mutimer DJ, Deterding K, Hofmann WP, Petersen J, Fasano M, Buti M, Berg T, Hansen BE, Sonneveld MJ, Wedemeyer H, Janssen HL; VIRGIL Surveillance Study Group. Zoutendijk R, et al. Among authors: buti m. Gut. 2013 May;62(5):760-5. doi: 10.1136/gutjnl-2012-302024. Epub 2012 Apr 5. Gut. 2013. PMID: 22490523
Entecavir treatment does not eliminate the risk of hepatocellular carcinoma in chronic hepatitis B: limited role for risk scores in Caucasians.
Arends P, Sonneveld MJ, Zoutendijk R, Carey I, Brown A, Fasano M, Mutimer D, Deterding K, Reijnders JG, Oo Y, Petersen J, van Bömmel F, de Knegt RJ, Santantonio T, Berg T, Welzel TM, Wedemeyer H, Buti M, Pradat P, Zoulim F, Hansen B, Janssen HL; VIRGIL Surveillance Study Group. Arends P, et al. Among authors: buti m. Gut. 2015 Aug;64(8):1289-95. doi: 10.1136/gutjnl-2014-307023. Epub 2014 Jul 10. Gut. 2015. PMID: 25011935 Clinical Trial.
Flares during long-term entecavir therapy in chronic hepatitis B.
Chi H, Arends P, Reijnders JG, Carey I, Brown A, Fasano M, Mutimer D, Deterding K, Oo YH, Petersen J, van Bommel F, de Knegt RJ, Santantonio TA, Berg T, Welzel TM, Wedemeyer H, Buti M, Pradat P, Zoulim F, Hansen BE, Janssen HL; VIRGIL Surveillance Study Group (European surveillance network for vigilance against viral resistance). Chi H, et al. Among authors: buti m. J Gastroenterol Hepatol. 2016 Nov;31(11):1882-1887. doi: 10.1111/jgh.13377. J Gastroenterol Hepatol. 2016. PMID: 27008918
635 results